6.79
price up icon0.30%   0.02
after-market After Hours: 6.79
loading
Emergent Biosolutions Inc stock is traded at $6.79, with a volume of 631.36K. It is up +0.30% in the last 24 hours and up +20.39% over the past month. Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
See More
Previous Close:
$6.77
Open:
$6.79
24h Volume:
631.36K
Relative Volume:
0.57
Market Cap:
$348.15M
Revenue:
$676.80M
Net Income/Loss:
$-8.60M
P/E Ratio:
-24.00
EPS:
-0.2829
Net Cash Flow:
$135.40M
1W Performance:
-0.15%
1M Performance:
+20.39%
6M Performance:
-17.30%
1Y Performance:
-22.31%
1-Day Range:
Value
$6.67
$6.845
1-Week Range:
Value
$6.48
$6.8962
52-Week Range:
Value
$4.36
$14.06

Emergent Biosolutions Inc Stock (EBS) Company Profile

Name
Name
Emergent Biosolutions Inc
Name
Phone
240-631-3200
Name
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Name
Employee
900
Name
Next Earnings Date
2026-11-04
Name
Latest SEC Filings
Name
EBS's Discussions on Twitter

Compare EBS vs TAK, TEVA, HLN, ZTS, VTRS

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
EBS icon
EBS
Emergent Biosolutions Inc
6.79 348.15M 676.80M -8.60M 135.40M -0.2829
TAK icon
TAK
Takeda Pharmaceutical Co Adr
18.86 60.23B 29.91B 1.30B 3.49B 0.4056
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
39.19 45.71B 17.53B 1.58B 444.18M 1.3457
HLN icon
HLN
Haleon Plc Adr
9.26 40.72B 14.54B 2.22B 2.58B 0.4871
ZTS icon
ZTS
Zoetis Inc
71.05 29.36B 9.51B 2.64B 2.14B 6.0361
VTRS icon
VTRS
Viatris Inc
17.83 20.48B 14.57B -296.50M 1.64B -0.259

Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-30-24 Initiated H.C. Wainwright Buy
Aug-22-24 Initiated Rodman & Renshaw Buy
Mar-07-24 Upgrade The Benchmark Company Hold → Buy
Nov-20-23 Resumed JP Morgan Underweight
Aug-29-23 Downgrade The Benchmark Company Buy → Hold
Apr-10-23 Upgrade The Benchmark Company Hold → Buy
Mar-17-23 Downgrade JP Morgan Neutral → Underweight
Nov-10-22 Downgrade The Benchmark Company Buy → Hold
Apr-29-22 Downgrade Cantor Fitzgerald Overweight → Neutral
Jan-20-22 Upgrade The Benchmark Company Hold → Buy
Nov-08-21 Downgrade The Benchmark Company Buy → Hold
May-05-21 Downgrade Argus Buy → Hold
Apr-07-21 Initiated The Benchmark Company Buy
Feb-24-21 Upgrade Chardan Capital Markets Neutral → Buy
Feb-19-21 Downgrade Chardan Capital Markets Buy → Neutral
Jan-08-21 Downgrade Wells Fargo Overweight → Equal Weight
Sep-14-20 Resumed JP Morgan Neutral
Jul-31-20 Reiterated Chardan Capital Markets Buy
Sep-12-19 Initiated Guggenheim Buy
Sep-04-19 Upgrade Wells Fargo Market Perform → Outperform
Nov-02-18 Upgrade Goldman Neutral → Buy
Aug-03-18 Reiterated Chardan Capital Markets Buy
Jun-13-18 Initiated Argus Buy
Apr-25-18 Downgrade Wells Fargo Outperform → Market Perform
Jan-24-18 Initiated Goldman Neutral
Jan-16-18 Reiterated Chardan Capital Markets Buy
Jun-28-16 Reiterated Singular Research Buy
Apr-15-16 Initiated Chardan Capital Markets Buy
Mar-28-16 Initiated Singular Research Buy
Feb-19-16 Initiated Wells Fargo Outperform
May-15-14 Initiated Summer Street Research Buy
May-31-11 Reiterated WBB Securities Strong Buy
Jan-10-11 Reiterated Wedbush Outperform
Nov-05-10 Reiterated Wedbush Outperform
Aug-18-10 Upgrade WBB Securities Buy → Strong Buy
Aug-06-10 Reiterated Caris & Company Buy
View All

Emergent Biosolutions Inc Stock (EBS) Latest News

pulisher
12:38 PM

Emergent BioSolutions Inc. (EBS) Investigation: Bronstein, Gewirt - The National Law Review

12:38 PM
pulisher
Sep 25, 2026

Precision Trading with Emergent Biosolutions Inc. (EBS) Risk Zones - Stock Traders Daily

Sep 25, 2026
pulisher
Sep 24, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc.EBS - prnewswire.com

Sep 24, 2026
pulisher
Sep 24, 2026

Emergent BioSolutions Inc (ER4.DU) Analyst insights, Price targets and RecommendationsYahoo Finance - Yahoo Finance Singapore

Sep 24, 2026
pulisher
Sep 20, 2026

Emergent BioSolutions stock steady as investors weigh recent fundamentals - AD HOC NEWS

Sep 20, 2026
pulisher
Sep 18, 2026

Emergent BioSolutions Inc. (EBS) Stock Analysis: Unpacking A 56.7% Potential Upside - DirectorsTalk Interviews

Sep 18, 2026
pulisher
Sep 17, 2026

Emergent BioSolutions stock rises on Q2 beat and guidance - AD HOC NEWS

Sep 17, 2026
pulisher
Sep 17, 2026

Emergent BioSolutions restarts Massachusetts manufacturing after $34.5M vaccine deal - bizjournals.com

Sep 17, 2026
pulisher
Sep 15, 2026

Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility - marketscreener.com

Sep 15, 2026
pulisher
Sep 15, 2026

Emergent: The MCM Engine Runs, But Naloxone Is Breaking Down - Seeking Alpha

Sep 15, 2026
pulisher
Sep 14, 2026

Emergent BioSolutions | 8-K: Current report - Moomoo

Sep 14, 2026
pulisher
Sep 14, 2026

Emergent BioSolutions presents transformation update, Q2 results, $40M restructuring savings and revised FY26 guidance - TradingView

Sep 14, 2026
pulisher
Sep 09, 2026

Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider - GlobeNewswire Inc.

Sep 09, 2026
pulisher
Sep 08, 2026

Emergent Biosolutions Inc (EBS) Fundamental & Financial Data - Stocktwits

Sep 08, 2026
pulisher
Sep 06, 2026

Emergent BioSolutions: Tough 2026 Outlook Warrant Rating Downgrade (NYSE:EBS) - Seeking Alpha

Sep 06, 2026
pulisher
Sep 04, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Emergent BioSolutions Inc. (EBS) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Sep 04, 2026
pulisher
Sep 04, 2026

Emergent Biosolutions Stock Price Forecast. Should You Buy EBS? - StockInvest.us

Sep 04, 2026
pulisher
Sep 04, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Emergent BioSolutio - The National Law Review

Sep 04, 2026
pulisher
Sep 03, 2026

Emergent BioSolutions repurchases $75 million in senior notes By Investing.com - Investing.com South Africa

Sep 03, 2026
pulisher
Sep 03, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Emergent BioSolutions Inc. (EBS) And Encourages Shareholders to Connect - ACCESS Newswire

Sep 03, 2026
pulisher
Sep 03, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Emergent BioS - The National Law Review

Sep 03, 2026
pulisher
Sep 03, 2026

Emergent BioSolutions Repurchases $75 Million of Debt at Discount - citybiz

Sep 03, 2026
pulisher
Sep 03, 2026

Emergent BioSolutions faces securities fraud pr... - Pluang

Sep 03, 2026
pulisher
Sep 03, 2026

Gaithersburg's Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS - BioBuzz

Sep 03, 2026
pulisher
Sep 03, 2026

Emergent BioSolutions repurchases $75 million in senior notes - investing.com

Sep 03, 2026
pulisher
Sep 03, 2026

Emergent BioSolutions Repurchases $75 Million of Senior Unsecured Notes, Reducing Debt to $364.7 Million - Quiver Quantitative

Sep 03, 2026
pulisher
Sep 03, 2026

Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes - marketscreener.com

Sep 03, 2026
pulisher
Sep 03, 2026

A $68 million cash outlay retires $75 million in Emergent bond debt - Stock Titan

Sep 03, 2026
pulisher
Sep 02, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Emergent BioSolutions Inc. (EBS) And Encourages Shareholders to Reach Out - ACCESS Newswire

Sep 02, 2026
pulisher
Sep 01, 2026

Emergent BioSolutions receives $24 million BARDA contract - grafa.com

Sep 01, 2026
pulisher
Sep 01, 2026

2026-09-01 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Shareholders to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse

Sep 01, 2026
pulisher
Sep 01, 2026

Emergent BioSolutions Inc. Receives Contract Modification Valued At Approximately USD 24 Million From The Biomedical Advanced Research And Development Authority To Supply CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) - marketscreener.com

Sep 01, 2026
pulisher
Sep 01, 2026

Emergent BioSolutions receives $24M anthrax vaccine contract By Investing.com - Investing.com Australia

Sep 01, 2026
pulisher
Sep 01, 2026

EBS Looks 11.9% Overvalued on GF Value™ Amid Challenging Growth Outlook - GuruFocus

Sep 01, 2026
pulisher
Sep 01, 2026

Emergent BioSolutions receives $24M anthrax vaccine contract - investing.com

Sep 01, 2026
pulisher
Sep 01, 2026

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) - The Manila Times

Sep 01, 2026
pulisher
Sep 01, 2026

Emergent BioSolutions Awarded $24M CYFENDUS Contract | EBS Stock News - Stock Titan

Sep 01, 2026
pulisher
Aug 31, 2026

Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray - Bioscience Association Manitoba

Aug 31, 2026
pulisher
Aug 31, 2026

EBS Looks 8.4% Overvalued on GF Value™ Amid Challenging Growth O - GuruFocus

Aug 31, 2026
pulisher
Aug 31, 2026

Emergent BioSolutions wins Canada contract for overdose spray By Investing.com - Investing.com Nigeria

Aug 31, 2026
pulisher
Aug 31, 2026

Emergent BioSolutions wins Canada contract for overdose spray - Investing.com Canada

Aug 31, 2026
pulisher
Aug 31, 2026

Emergent BioSolutions Awarded Canadian Government Standing Offer for NARCAN Nasal Spray - Quiver Quantitative

Aug 31, 2026
pulisher
Aug 31, 2026

Canadian public agencies can buy NARCAN for three years; the spray lasts four - Stock Titan

Aug 31, 2026
pulisher
Aug 30, 2026

2026-08-30 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Investors to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse

Aug 30, 2026
pulisher
Aug 30, 2026

Emergent BioSolutions Inc. (EBS) Options Chain - finance.yahoo.com

Aug 30, 2026
pulisher
Aug 30, 2026

Emergent Biosolutions Inc (EBS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Aug 30, 2026
pulisher
Aug 25, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Emergent BioSolutions Inc. (EBS) And Encourages Stockholders to Reach Out - ACCESS Newswire

Aug 25, 2026
pulisher
Aug 24, 2026

Emergent (EBS) Shares: Gains 1.97% to Reach $5.18 in the Current Update; Level Watch: Traders Can Monitor the $4.92-$5.44 Range in the Available RecordMedian Line - careplusvn.com

Aug 24, 2026
pulisher
Aug 21, 2026

EBS Reinstated by JP Morgan -- Current Rating Underweight - GuruFocus

Aug 21, 2026
pulisher
Aug 21, 2026

2026-08-21 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Stockholders to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse

Aug 21, 2026
pulisher
Aug 21, 2026

JPMorgan Chase & Co. Begins Coverage on Emergent Biosolutions (NYSE:EBS) - MarketBeat

Aug 21, 2026

Emergent Biosolutions Inc Stock (EBS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$19.77
price down icon 0.18%
RDY RDY
$12.25
price down icon 0.41%
$22.31
price down icon 0.18%
$138.40
price down icon 0.39%
$475.45
price up icon 0.69%
$17.83
price up icon 2.35%
Cap:     |  Volume (24h):